Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 224-236

  Bartzokis, George ^a,b,c,d   Tishler, Todd A ^c,e   Shin, Il Seon ^a,f   Lu, Po H ^a,e   Cummings, Jeffrey L ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of Brain Mapping   (United States)

^c Gtr Los Angeles VA Hlthcare System   (United States)

^d CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Chonnam National University Medical School   (South Korea)

Author keywords

Age at onset; Aging; Alzheimer's disease; Amyloid; Brain development; Degeneration; Dementia; Ferritin; Free radicals; Gender; Iron; Lewy body; Myelin; Neuritic plaques; Oligodendrocytes; Parkinson's disease; Risk factor; Sex; Synucleinopathy; Tau; synuclein

Indexed keywords

FERRITIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; BRAIN FERRITIN IRON LEVEL; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BRAIN LEVEL; FIELD DEPENDENT RELAXATION RATE METHOD; FRONTAL LOBE; GENE; GLOBUS PALLIDUS; HEMOCHROMATOSIS GENE; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PUTAMEN; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TOXICITY; WHITE MATTER;

EID: 1842451926     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.019     Document Type: Article

References (76)

1. BARTZOKIS, G., M. BECKSON, P.M. Lu et al. 2001. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch. Gen. Psychiatry 58: 461-465.
2. BARTZOKIS, G. 2004. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 25: 5-18.
3. BARTZOKIS, G. 2004. Quadratic trajectories of brain myelin content: unifying construct for neuropsychiatrie disorders. Neurobiol. Aging 25: 49-62.
4. CONNOR, J.R. & S.L. MENZIES. 1996. Relationship of iron to oligodendrocytes and myelination. Glia 17: 83-93.
5. ERB, G.L., D.L. OSTERBUR & S.M. LEVINE. 1996. The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry. Brain Res. Dev. Brain Res. 93: 120-128.
6. MORATH, D.J. & M. MAYER-PROSCHEL. 2001. Iron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes. Dev. Biol. 237: 232-243.
7. POWER, J., M. MAYER-PROSCHEL, J. SMITH et al. 2002. Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions. Dev. Biol. 245: 362-375.
8. SMITH, M.A., C.A. ROTTKAMP, A. NUNOMURA et al. 2000. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502: 139-144.
9. RONCAGLIOLO, M., M. GARRIDO, T. WALTER et al. 1998. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. Am. J. Clin. Nutr. 68: 683-690.
10. BARTZOKIS, G., D. SULTZER, J. MINTZ et al. 1994. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol. Psychiatry 35: 480-487.
11. BARTZOKIS, G., M. BECKSON, D.B. HANCE et al. 1997. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15: 29-35.
12. BARTZOKIS, G., D. SULTZER, B.J. CUMMINGS et al. 2000. In vivo evaluation of brain iron in Alzheimer's disease and normal controls using magnetic resonance imaging. Arch. Gen. Psychiatry 57: 47-53.
13. HALLGREN, B. & P. SOURANDER. 1958. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3: 41-51.
14. KLINTWORTH, G.K. 1973. Huntington's chorea - morphologic contributions of a century. In Advances in Neurology. Vol. 1: Huntington's Chorea, 1872-1972, pp. 353-368. Raven Press. New York.
15. BARTZOKIS, G., J. MINTZ, D. SULTZER et al. 1994. In vivo MR evaluation of age-related increases in brain iron. Am. J. Neuroradiol. 15: 1129-1138.
16. CONNOR, J.R., B.S. SNYDER, P. AROSIO et al. 1995. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65: 717-724.
17. HULET, S.W., S. MENZIES & J.R. CONNOR. 2002. Ferritin binding in the developing mouse brain follows a pattern similar to myelination and is unaffected by the jimpy mutation. Dev. Neurosci. 24: 208-213.
18. GERBER, M.R. & J.R. CONNOR. 1989. Do oligodendrocytes mediate iron regulation in the human brain? Ann. Neurol. 26: 95-98.
19. TANG, Y., J.R. NYENGAARD, B. PAKKENBERG et al. 1997. Age-induced white matter changes in the human brain: a stereological investigation. Neurobiol. Aging 18: 609-615.
20. MARNER, L., J.R. NYENGAARD, Y. TANG et al. 2003. Marked loss of myelinated nerve fibers in the human brain with age. J. Comp. Neurol. 462: 144-152.
21. HALLIWELL, B. & J.M.C. GUTTERIDGE. 1988. Iron as biological pro-oxidant. ISI Atlas Sci. Biochem. 1: 48-52.
22. BARTZOKIS, G., J.L. CUMMINGS, C.H. MARKHAM et al. 1999. MRI evaluation of brain iron in earlier-and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17: 213-222.
23. BARTZOKIS, G., J. CUMMINGS, S. PERLMAN et al. 1999. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56: 569-574.
24. BARTZOKIS, G. & T.A. TISHLER. 2000. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell. Mol. Biol. 46: 821-833.
25. MOALEM, S., M.E. PERCY, D.F. ANDREWS et al. 2000. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am. J. Med. Genet. 93: 58-66.
26. SAMPIETRO, M., L. CAPUTO, A. CASATTA et al. 2001. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Aging. 22: 563-568.
27. COMBARROS, O., M. GARCIA-ROMAN, A. FONTALBA et al. 2003. Interaction of the h63d mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 15: 151-154.
28. BARTZOKIS, G., M. ARAVAGIRI, W.H. OLDENDORF et al. 1993. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn. Reson. Med. 29: 459-464.
29. FLOYD, R.A. & J.M. CARNEY. 1993. The role of metal ions in oxidative processes and aging. Toxicol. Ind. Health 9: 197-214.
30. MORRIS, C.M., J.M. CANDY, A.E. OAKLEY et al. 1992. Histochemical distribution of non-haem iron in the human brain. Acta Anat. (Basel) 144: 235-257.
31. VYMAZAL, J., M. HAJEK, N. PATRONAS et al. 1995. The quantitative relation between T1-weighted and T2-weighted MRI of normal gray matter and iron concentration. J. Magn. Reson. Imaging 5: 554-560.
32. VYMAZAL, J., R.A. BROOKS, C. BAUMGARNER et al. 1996. The relation between brain iron and NMR relaxation times: an in vitro study. Magn. Reson. Med. 35: 56-61.
33. VYMAZAL, J., O. ZAK, J.W. BULTE et al. 1996. T1 and T2 of ferritin solutions: effect of loading factor. Magn. Reson. Med. 36: 61-65.
34. VYMAZAL, J., R.A. BROOKS, N. PATRONAS et al. 1995. Magnetic resonance imaging of brain iron in health and disease. J. Neurol. Sci. 134(suppl.): 19-26.
35. BULTE, J.W., G.F. MILLER, J. VYMAZAL et al. 1997. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn. Reson. Med. 37: 530-536.
36. PANTELATOS, A. & F. FORNADI. 1993. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Adv. Neurol. 60: 690-697.
37. KOSTIC, V.S., S.R. FILIPOVIC, D. LECIC et al. 1994. Effect of age at onset on frequency of depression in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57: 1265-1267.
38. MAYEUX, R., K. MARDER, L.J. COTE et al. 1995. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993 [see comments]. Am. J. Epidemiol. 142: 820-827.
39. DE RIJK, M.C., C. TZOURIO, M.M. BRETELER et al. 1997. Prevalence of parkinsonism and Parkinson's disease in Europe - The EuroParkinson Collaborative Study: European community concerted action on the epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62: 10-15.
40. DEXTER, D.T., J. SIAN, P. JENNER et al. 1993. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. In Parkinson's Disease: From Basic Research to Treatment, pp. 273-281. Raven Press. New York.
41. FRIEDMAN, A. 1994. Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neurol. Scand. 89: 258-261.
42. WU, R.M., H.C. CHIU, M. WANG et al. 1993. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dement. Sect. 5: 127-133.
43. KOSTIC, V.S., S. PRZEDBORSKI, E. FLASTER et al. 1991. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41: 202-205.
44. GOLBE, L.I. 1991. Young-onset Parkinson's disease: a clinical review. Neurology 41: 168-173.
45. WAGNER, M.L., M.N. FEDAK, J.I. SAGE et al. 1996. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann. Clin. Lab. Sci. 26: 389-395.
46. BARKER, W.W., C.A. LUIS, A. KASHUBA et al. 2002. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer's Dis. Assoc. Disord. 16: 203-212.
47. COLOSIMO, C., A.J. HUGHES, L. KILFORD et al. 2003. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74: 852-856.
48. FOLSTEIN, M.F., S.E. FOLSTEIN & P.R. MCHUGH. 1975. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198.
49. MCKHANN, G., D. DRACHMAN, M. FOLSTEIN et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
50. PULLIAM, J.F., C.D. JENNINGS, R.J. KRYSCIO et al. 2003. Association of hfe mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with apoE. Am. J. Med. Genet. 119B: 48-53.
51. DEMARQUAY, G., A. SETIEY, Y. MOREL et al. 2000. Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov. Disord. 15: 1204-1209.
52. DEKKER, M.C., P.C. GIESBERGEN, O.T. NJAJOU et al. 2003. Mutations in the hemochromatosis gene (hfe), Parkinson's disease, and parkinsonism. Neurosci. Lett. 348: 117-119.
53. KRAEMER, H.C., J.A. YESAVAGE, J.L. TAYLOR et al. 2000. How can we learn about developmental processes from cross-sectional studies, or can we? Am. J. Psychiatry 157: 163-171.
54. YAKOVLEV, P.I. & A.R. LECOURS. 1967. Regional development of the brain in early life. Blackwell Sci. Pub. Boston.
55. JOSHI, J.G., S.R. SCZEKAN & J.T. FLEMING. 1989. Ferritin - a general metal detoxicant. Biol. Trace Elem. Res. 21: 105-110.
56. DE LOS MONTEROS, A.E., R.A. KORSAK, T. TRAN et al. 2000. Dietary iron and the integrity of the developing rat brain: a study with the artificially-reared rat pup. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 501-515.
57. ANGGARD, E. 1994. Nitric oxide: mediator, murderer, and medicine [see comments]. Lancet 343: 1199-1206.
58. DAI, L., P.G. WINYARD, Z. ZHANG et al. 1996. Ascorbate promotes low density lipoprotein oxidation in the presence of ferritin. Biochim. Biophys. Acta 1304: 223-228.
59. DOUBLE, K.L., M. MAYWALD, M. SCHMITTEL et al. 1998. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70: 2492-2499.
60. HALLIWELL, B. & J.M. GUTTERIDGE. 1986. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246: 501-514.
61. BLISSMAN, G., S. MENZIES, J. BEARD et al. 1996. The expression of ferritin subunits and iron in oligodendrocytes in neonatal porcine brains. Dev. Neurosci. 18: 274-281.
62. ROGERS, J.T., J.D. RANDALL, P.S. EDER et al. 2002. Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region. J. Mol. Neurosci. 19: 77-82.
63. MAYNARD, C.J., R. CAPPAI, I. VOLITAKIS et al. 2002. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277: 44670-44676.
64. ZOU, K., J.S. GONG, K. YANAGISAWA et al. 2002. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22: 4833-4841.
65. ATWOOD, C.S., R.D. MOIR, X. HUANG et al. 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273: 12817-12826.
66. CURTAIN, C.C., F. ALI, I. VOLITAKIS et al. 2001. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276: 20466-20473.
67. GARZON-RODRIGUEZ, W., A.K. YATSIMIRSKY & C.G. GLABE. 1999. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's Aβ peptide studied by fluorescence. Bioorg. Med. Chem. Lett. 9: 2243-2248.
68. LOSKE, C., A. GERDEMANN, W. SCHEPL et al. 2000. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 267: 4171-4178.
69. KIURU, S., O. SALONEN & M. HALTIA. 1999. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann. Neurol. 45: 305-311.
70. TORP, R., E. HEAD & C.W. COTMAN. 2000. Ultrastructural analyses of beta-amyloid in the aged dog brain: neuronal beta-amyloid is localized to the plasma membrane. Prog. Neuropsychopharmacol. Biol. Psychiatry 24: 801-810.
71. GOLTS, N., H. SNYDER, M. FRASIER et al. 2002. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277: 16116-16123.
72. GIASSON, B.I., M.S. FORMAN, M. HIGUCHI et al. 2003. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
73. ARIMA, K., S. HIRAI, N. SUNOHARA et al. 1999. Cellular co-localization of phosphorylated tau-and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 843: 53-61.
74. PIAO, Y.S., S. HAYASHI, M. HASEGAWA et al. 2001. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol. (Berlin) 101: 285-293.
75. CHERNY, R.A., C.S. ATWOOD, M.E. XILINAS et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676.
76. MCLACHLAN, D.R.C., A.J. DALTON, T.P. KRUCK et al. 1991. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308.